Oral administration of type-II collagen suppresses IL-17-associated RANKL expression of CD4+ T cells in collagen-induced arthritis

Immunology Letters

Volumn 117, Issue 1, 2008, Pages 16-25

  Ju, Ji Hyeon ^c   Cho, Mi La ^c   Jhun, Joo Youn ^a   Park, Min Jung ^a   Oh, Hye Joa ^a   Min, So Youn ^a   Cho, Young Gyu ^a   Hwang, Seu Yun ^b   Kwok, Seung Ki ^a   Seo, Soo Hong ^a   Yoon, Chong Hyeon ^a   Park, Sung Hwan ^a   Kim, Ho Youn ^a  

^a The Catholic University of Korea   (South Korea)

^b Hankyong National University   (South Korea)

^c NONE

Author keywords

CD4+ T cells; Collagen induced arthritis; IL 17; Oral tolerance; RANKL

Indexed keywords

COLLAGEN TYPE 2; INTERLEUKIN 10; INTERLEUKIN 17; OSTEOCLAST DIFFERENTIATION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG INHIBITION; IMMUNOLOGICAL TOLERANCE; MALE; MOUSE; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIGENS, CD3; ARTHRITIS, EXPERIMENTAL; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; COLLAGEN TYPE II; GENE EXPRESSION; IMMUNE TOLERANCE; INTERLEUKIN-10; INTERLEUKIN-17; JOINTS; MALE; MICE; MICE, INBRED DBA; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

EID: 40649110475     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2007.09.011     Document Type: Article

References (16)

1. Weiner H.L., Friedman A., Miller A., Khoury S.J., Al-Sabbagh A., Santos L., et al. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol 12 (1994) 809-837
2. Friedman A., and Weiner H.L. Induction of energy or active suppression following oral tolerance is determined by antigen dosage. Proc Natl Acad Sci USA 91 (1994) 6688-6692
3. Mayer L., and Shao L. Therapeutic potential of oral tolerance. Nat Rev Immunol 4 (2004) 407-419
4. Trentham D.E., Dynesius-Trentham R.A., Orav E.J., Combitchi D., Lorenzo C., Sewell K.L., et al. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 261 (1993) 1727-1730
5. Min S.Y., Hwang S.Y., Park K.S., Lee J.S., Lee K.E., Kim K.W., et al. Induction of IL-10-producing CD4+ CD25+ T cells in animal model of collagen-induced arthritis by oral administration of type II collagen. Arthritis Res Ther 6 (2004) R213-R219
6. Min S.Y., Park K.S., Cho M.L., Kang J.W., Cho Y.G., Hwang S.Y., et al. Antigen-induced, tolerogenic CD11c+, CD11b+ dendritic cells are abundant in Peyer's patches during the induction of oral tolerance to type II collagen and suppress experimental collagen-induced arthritis. Arthritis Rheum 54 (2006) 887-898
7. Horwood N.J., Kartsogiannis V., Quinn J.M., Romas E., Martin T.J., and Gillespie M.T. Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun 265 (1999) 144-150
8. Kong Y.Y., Feige U., Sarosi I., Bolon B., Tafuri A., Morony S., et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402 (1999) 304-309
9. Kotake S., Udagawa N., Hakoda M., Mogi M., Yano K., Tsuda E., et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 44 (2001) 1003-1012
10. Kolls J.K., and Linden A. Interleukin-17 family members and inflammation. Immunity 21 (2004) 467-476
11. Cho M.L., Kang J.W., Moon Y.M., Nam H.J., Jhun J.Y., Heo S.B., et al. STAT3 and NF-kappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. J Immunol 176 (2006) 5652-5661
12. Ferretti S., Bonneau O., Dubois G.R., Jones C.E., and Trifilieff A. IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger. J Immunol 170 (2003) 2106-2112
13. Rosloniec E.F., Cremer M., Kang A., and Myers L.K. Collagen-induced arthritis. Immunology 15.5 (1996) 1-19
14. Kim W.U., Lee W.K., Ryoo J.W., Kim S.H., Kim J., Youn J., et al. Suppression of collagen-induced arthritis by single administration of poly(lactic-co-glycolic acid) nanoparticles entrapping type II collagen: a novel treatment strategy for induction of oral tolerance. Arthritis Rheum 46 (2002) 1109-1120
15. Fossiez F., Djossou O., Chomarat P., Flores-Romo L., Ait-Yahia S., Maat C., et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 183 (1996) 2593-2603
16. Lubberts E., Koenders M.I., and Van den Berg W.B. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther 7 (2005) 29-37